Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00989963 · ClinicalTrials.gov registry record · Phase 2
Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
A Phase 2 study of Pulmonary Arterial Hypertension, sponsored by Lung Biotechnology PBC.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 17
- Study locations
NCT00989963 is a Phase 2 study of Pulmonary Arterial Hypertension that has completed, run by Lung Biotechnology PBC. The registered enrollment target is 36 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (92% lower). The trial reports 17 study locations across 6 states.
The verdict
NCT00989963, a Phase 2 study of Pulmonary Arterial Hypertension, has completed, sponsored by Lung Biotechnology PBC.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a 12-week, international, multicenter, double-blind, three-group, dose-response study to assess the safety and efficacy of BPS-MR in patients with PAH. Eligible patients will have been previously diagnosed with PAH and will be on a stable course of an ERA and/or PDE-5 inhibitor for at least 60 days prior to Baseline. Patients will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio and will be stratified by PAH background therapy (Endothelium Receptor Antagonist (ERA), Phosphodiesterase-5 (PDE-5), and both). The treatment groups consist of one Maximum Tolerated Dose (MTD) and two Fixed Dose (FD) groups. Following randomization, patients will begin taking active drug (60µg) orally twice daily. Patients will visit their investigational site at Week 6 and Week 12 for study evaluations.
Conditions Studied
Interventions
- DRUG Beraprost Sodium Modified Release
Study Locations (17)
Other
- Universite Libre de Bruxelles - Bruxellas
- Catholic University of Leuven - Leuven
- General Teaching Hospital - Prague
- Klinikum der Universitat zu Koln - Cologne
- Medizinische Klinik und Poliklinik - Dresden
- Abt. Innere Medizin III, Medizinische Universitatsklinik - Heidelberg
- Universitatsklinik Leipzig Abteilung Pulmologie - Leipzig
- Mater Misericordiae University Hospital Ltd. - Dublin
- Institutul de Urgenta pentru Boli - Bucharest
- Institutul National de Pneumologie - Bucharest
- Institutul de Boli Cardiovasculare - Lasi
New York
- Beth Israel Medical Center - New York
- Albert Einstein College of Medicine - The Bronx
California
- Harbor-UCLA Medical Center - Torrance
Illinois
- Edward Heart Hospital - Naperville
Pennsylvania
- Allegheny General Hospital - Pittsburgh
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2010-02-01 |
| Est. Completion | 2011-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00989963
The ClinicalTrials.gov registry entry for NCT00989963 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (92% lower). The listed sponsor is Lung Biotechnology PBC, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Beraprost Sodium Modified Release is the first listed.
NCT00989963 reports 17 study locations spanning 6 distinct geographic areas - top geographies include Other, New York, California.
Frequently Asked Questions
What is clinical trial NCT00989963 about?
NCT00989963 is a clinical study titled "Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)". This is a 12-week, international, multicenter, double-blind, three-group, dose-response study to assess the safety and efficacy of BPS-MR in patients with PAH. Eligible patients will have been previously diagnosed with PAH and will be on a stable course of an ERA and/or PDE-5 inhibitor for at least ...
What is the current status of trial NCT00989963?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2010-02-01. Estimated completion is 2011-09-13.
What conditions does trial NCT00989963 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
What interventions are being tested in trial NCT00989963?
The interventions under investigation include: Beraprost Sodium Modified Release (DRUG).
Who is sponsoring clinical trial NCT00989963?
This trial is sponsored by Lung Biotechnology PBC, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00989963 being conducted?
This trial has 17 study locations across California, Illinois, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
Repurposing Valsartan May Protect Against Pulmonary Hypertension
RECRUITING · Phase 2
-
Spironolactone for Pulmonary Arterial Hypertension
RECRUITING · Phase 2
-
129 Xenon Imaging in Patients Treated With Sotatercept
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.